{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:27:19Z","timestamp":1795030039054,"version":"4.10.2"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cornell COVID-19 seed grant"},{"DOI":"10.13039\/100006792","name":"Hartwell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic reprogramming of the tumor microenvironment (TME) and poor immunogenicity are two of the challenges that cancer immunotherapies have to overcome for improved clinical benefits. Among various immunosuppressive metabolites that keep anti-tumor immunity in check, the tryptophan catabolite kynurenine (Kyn) is an attractive target for blockade given its role in mediating immunosuppression through multiple pathways. Here, we present a local chemo-immunometabolic therapy through injection of a supramolecular hydrogel concurrently releasing doxorubicin that induces immunogenic tumor cell death and kynureninase that disrupts Kyn-mediated immunosuppressive pathways in TME. The combination synergically enhances tumor immunogenicity and unleashes anti-tumor immunity. In mouse models of triple negative breast cancer and melanoma, a single low dose peritumoral injection of the therapeutic hydrogel promotes TME transformation toward more immunostimulatory, which leads to enhanced tumor suppression and extended mouse survival. In addition, the systemic anti-tumor surveillance induced by the local treatment exhibits an abscopal effect and prevents tumor relapse post-resection. This versatile approach for local chemo-immunometabolic therapy may serve as a general strategy for enhancing anti-tumor immunity and boosting the efficacy of cancer immunotherapies.<\/jats:p>","DOI":"10.1038\/s41467-022-31579-8","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T07:02:44Z","timestamp":1656745364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["An in situ hydrogel-mediated chemo-immunometabolic cancer therapy"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8217-7667","authenticated-orcid":false,"given":"Bo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-0349","authenticated-orcid":false,"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6534-8428","authenticated-orcid":false,"given":"Julia S.","family":"Caserto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-7526","authenticated-orcid":false,"given":"Minglin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"key":"31579_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"31579_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev-cancerbio-030518-055552","volume":"3","author":"M Dougan","year":"2019","unstructured":"Dougan, M., Dranoff, G. & Dougan, S. K. Cancer immunotherapy: beyond checkpoint blockade. Annu. Rev. Cancer Biol. 3, 55\u201375 (2019).","journal-title":"Annu. Rev. Cancer Biol."},{"key":"31579_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed, M. F. & Chen, L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175, 313\u2013326 (2018).","journal-title":"Cell"},{"key":"31579_CR4","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"31579_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"31579_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"31579_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","volume":"21","author":"K DePeaux","year":"2021","unstructured":"DePeaux, K. & Delgoffe, G. M. Metabolic barriers to cancer immunotherapy. Nat. Rev. Immunol. 21, 785\u2013797 (2021).","journal-title":"Nat. Rev. Immunol"},{"key":"31579_CR8","doi-asserted-by":"publisher","first-page":"e55185","DOI":"10.7554\/eLife.55185","volume":"9","author":"AR Lim","year":"2020","unstructured":"Lim, A. R., Rathmell, W. K. & Rathmell, J. C. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. Elife 9, e55185 (2020).","journal-title":"Elife"},{"key":"31579_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-cancerbio-030518-055817","volume":"5","author":"DG Roy","year":"2020","unstructured":"Roy, D. G., Kaymak, I., Williams, K. S., Ma, E. H. & Jones, R. G. Immunometabolism in the tumor microenvironment. Annu. Rev. Cancer Biol. 5, 137\u2013159 (2020).","journal-title":"Annu. Rev. Cancer Biol."},{"key":"31579_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41416-019-0664-6","volume":"122","author":"CA Opitz","year":"2020","unstructured":"Opitz, C. A. et al. The therapeutic potential of targeting tryptophan catabolism in cancer. Br. J. Cancer 122, 30\u201344 (2020).","journal-title":"Br. J. Cancer"},{"key":"31579_CR11","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-18-2882","volume":"25","author":"BW Labadie","year":"2019","unstructured":"Labadie, B. W., Bao, R. & Luke, J. J. Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan\u2013kynurenine\u2013aryl hydrocarbon axis. Clin. Cancer Res. 25, 1462\u20131471 (2019).","journal-title":"Clin. Cancer Res."},{"key":"31579_CR12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","volume":"18","author":"M Platten","year":"2019","unstructured":"Platten, M., Nollen, E. A. A., R\u00f6hrig, U. F., Fallarino, F. & Opitz, C. A. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat. Rev. Drug Discov. 18, 379\u2013401 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"31579_CR13","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","volume":"77","author":"GC Prendergast","year":"2017","unstructured":"Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B. & Muller, A. J. Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res. 77, 6795\u20136811 (2017).","journal-title":"Cancer Res."},{"key":"31579_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1172\/JCI31178","volume":"117","author":"DH Munn","year":"2007","unstructured":"Munn, D. H. & Mellor, A. L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117, 1147\u20131154 (2007).","journal-title":"J. Clin. Invest."},{"key":"31579_CR15","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","volume":"185","author":"JD Mezrich","year":"2010","unstructured":"Mezrich, J. D. et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190\u20133198 (2010).","journal-title":"J. Immunol."},{"key":"31579_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","volume":"478","author":"CA Opitz","year":"2011","unstructured":"Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197\u2013203 (2011).","journal-title":"Nature"},{"key":"31579_CR17","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","volume":"11","author":"LF Campesato","year":"2020","unstructured":"Campesato, L. F. et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat. Commun. 11, 4011 (2020).","journal-title":"Nat. Commun."},{"key":"31579_CR18","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1158\/0008-5472.CAN-12-0569","volume":"72","author":"M Platten","year":"2012","unstructured":"Platten, M., Wick, W. & Van Den Eynde, B. J. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 72, 5435\u20135440 (2012).","journal-title":"Cancer Res."},{"key":"31579_CR19","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.celrep.2016.10.079","volume":"17","author":"LA Van de Velde","year":"2016","unstructured":"Van de Velde, L. A. et al. Stress kinase GCN2 Controls the proliferative fitness and trafficking of cytotoxic T cells independent of environmental amino acid sensing. Cell Rep. 17, 2247\u20132258 (2016).","journal-title":"Cell Rep."},{"key":"31579_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.immuni.2017.01.005","volume":"46","author":"G Mondanelli","year":"2017","unstructured":"Mondanelli, G. et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. Immunity 46, 233\u2013244 (2017).","journal-title":"Immunity"},{"key":"31579_CR21","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger, S. et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. 5, 200ra116 (2013).","journal-title":"Sci. Transl. Med"},{"key":"31579_CR22","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20130066","volume":"210","author":"RB Holmgaard","year":"2013","unstructured":"Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D. & Allison, J. P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210, 1389\u20131402 (2013).","journal-title":"J. Exp. Med."},{"key":"31579_CR23","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","volume":"125","author":"S Ninomiya","year":"2015","unstructured":"Ninomiya, S. et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125, 3905\u20133916 (2015).","journal-title":"Blood"},{"key":"31579_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2051-1426-2-3","volume":"2","author":"S Spranger","year":"2014","unstructured":"Spranger, S. et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. J. Immunother. Cancer 2, 3 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"31579_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","volume":"14","author":"K Tang","year":"2021","unstructured":"Tang, K., Wu, Y. H., Song, Y. & Yu, B. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. J. Hematol. Oncol. 14, 68 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"31579_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1146\/annurev-cancerbio-030419-033635","volume":"4","author":"BJ Van Den Eynde","year":"2020","unstructured":"Van Den Eynde, B. J., Van Baren, N. & Baurain, J. F. Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma? Annu. Rev. Cancer Biol. 4, 241\u2013256 (2020).","journal-title":"Annu. Rev. Cancer Biol."},{"key":"31579_CR27","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3389\/fimmu.2019.01801","volume":"10","author":"J G\u00fcnther","year":"2019","unstructured":"G\u00fcnther, J., D\u00e4britz, J. & Wirthgen, E. Limitations and off-target effects of tryptophan-related IDO inhibitors in cancer treatment. Front. Immunol. 10, 1801 (2019).","journal-title":"Front. Immunol."},{"key":"31579_CR28","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1158\/1078-0432.CCR-13-1610","volume":"20","author":"CM Lovly","year":"2014","unstructured":"Lovly, C. M. & Shaw, A. T. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin. Cancer Res. 20, 2249\u20132256 (2014).","journal-title":"Clin. Cancer Res."},{"key":"31579_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s40425-019-0667-0","volume":"7","author":"A Osipov","year":"2019","unstructured":"Osipov, A., Saung, M. T., Zheng, L. & Murphy, A. G. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. J. Immunother. Cancer 7, 224 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"31579_CR30","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong, L. et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct. Target. Ther. 6, 201 (2021).","journal-title":"Signal Transduct. Target. Ther"},{"key":"31579_CR31","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nbt.4180","volume":"36","author":"TA Triplett","year":"2018","unstructured":"Triplett, T. A. et al. Reversal of indoleamine 2,3-dioxygenase\u2013mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nat. Biotechnol. 36, 758\u2013764 (2018).","journal-title":"Nat. Biotechnol"},{"key":"31579_CR32","doi-asserted-by":"publisher","first-page":"2007247","DOI":"10.1002\/adma.202007247","volume":"33","author":"Z Zeng","year":"2021","unstructured":"Zeng, Z. et al. Activatable polymer nanoenzymes for photodynamic immunometabolic cancer therapy. Adv. Mater. 33, 2007247 (2021).","journal-title":"Adv. Mater"},{"key":"31579_CR33","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.3389\/fimmu.2019.01654","volume":"10","author":"JW Opzoomer","year":"2019","unstructured":"Opzoomer, J. W., Sosnowska, D., Anstee, J. E., Spicer, J. F. & Arnold, J. N. Cytotoxic chemotherapy as an immune stimulus: a molecular perspective on turning up the immunological heat on cancer. Front. Immunol. 10, 1654 (2019).","journal-title":"Front. Immunol."},{"key":"31579_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel, L., Apetoh, L., Ghiringhelli, F. & Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59\u201373 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"31579_CR35","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L., Humeau, J., Buqu\u00e9, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u2013741 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"31579_CR36","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","volume":"3","author":"LA Emens","year":"2015","unstructured":"Emens, L. A. & Middleton, G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol. Res. 3, 436\u2013443 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"31579_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54\u201361 (2007).","journal-title":"Nat. Med."},{"key":"31579_CR38","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","volume":"202","author":"N Casares","year":"2005","unstructured":"Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691\u20131701 (2005).","journal-title":"J. Exp. Med."},{"key":"31579_CR39","first-page":"1789","volume":"60","author":"OJ Arola","year":"2000","unstructured":"Arola, O. J. et al. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 60, 1789\u20131792 (2000).","journal-title":"Cancer Res."},{"key":"31579_CR40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/cgt.2017.9","volume":"24","author":"L Ansari","year":"2017","unstructured":"Ansari, L. et al. The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: A systematic review of clinical trials. Cancer Gene Ther. 24, 189\u2013193 (2017).","journal-title":"Cancer Gene Ther."},{"key":"31579_CR41","doi-asserted-by":"publisher","first-page":"370ra180","DOI":"10.1126\/scitranslmed.aag2942","volume":"8","author":"D Mathios","year":"2016","unstructured":"Mathios, D. et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci. Transl. Med. 8, 370ra180 (2016).","journal-title":"Sci. Transl. Med."},{"key":"31579_CR42","first-page":"E1239","volume":"115","author":"D Samanta","year":"2018","unstructured":"Samanta, D. et al. Chemotherapy induces enrichment of CD47+\/CD73+\/PDL1+ immune evasive triple-negative breast cancer cells. Proc. Natl Acad. Sci. USA 115, E1239\u2013E1248 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31579_CR43","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1172\/JCI131859","volume":"130","author":"MH Oh","year":"2020","unstructured":"Oh, M. H. et al. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J. Clin. Invest. 130, 3865\u20133884 (2020).","journal-title":"J. Clin. Invest."},{"key":"31579_CR44","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/01.cji.0000436722.46675.4a","volume":"36","author":"MG Lechner","year":"2013","unstructured":"Lechner, M. G. et al. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J. Immunother. 36, 477\u2013489 (2013).","journal-title":"J. Immunother."},{"key":"31579_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12864-019-6344-3","volume":"21","author":"W Zhong","year":"2020","unstructured":"Zhong, W. et al. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. BMC Genomics 21, 2 (2020).","journal-title":"BMC Genomics"},{"key":"31579_CR46","doi-asserted-by":"publisher","first-page":"2001628","DOI":"10.1002\/adma.202001628","volume":"32","author":"J Chen","year":"2020","unstructured":"Chen, J. et al. An adhesive hydrogel with \u201cLoad-Sharing\u201d effect as tissue bandages for drug and cell delivery. Adv. Mater. 32, 2001628 (2020).","journal-title":"Adv. Mater."},{"key":"31579_CR47","doi-asserted-by":"publisher","first-page":"2101714","DOI":"10.1002\/adhm.202101714","volume":"11","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Sustained delivery of SARS-CoV-2 RBD subunit vaccine using a high affinity injectable hydrogel scaffold. Adv. Healthc. Mater. 11, 2101714 (2022).","journal-title":"Adv. Healthc. Mater"},{"key":"31579_CR48","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018).","journal-title":"Nature"},{"key":"31579_CR49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1158\/0008-5472.CAN-16-2684","volume":"78","author":"FP Canale","year":"2018","unstructured":"Canale, F. P. et al. CD39 expression defines cell exhaustion in tumor-infiltrating CD8+ T cells. Cancer Res. 78, 115\u2013128 (2018).","journal-title":"Cancer Res."},{"key":"31579_CR50","doi-asserted-by":"publisher","first-page":"20410","DOI":"10.1073\/pnas.0810114105","volume":"105","author":"J Yuan","year":"2008","unstructured":"Yuan, J. et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA 105, 20410\u201320415 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31579_CR51","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.1021\/acsnano.6b04989","volume":"10","author":"Y Ye","year":"2016","unstructured":"Ye, Y. et al. Synergistic transcutaneous immunotherapy enhances antitumor immune responses through delivery of checkpoint Inhibitors. ACS Nano 10, 8956\u20138963 (2016).","journal-title":"ACS Nano"},{"key":"31579_CR52","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1021\/acs.nanolett.9b02306","volume":"19","author":"D Liu","year":"2019","unstructured":"Liu, D. et al. Redox-activated porphyrin-based liposome remote-loaded with indoleamine 2,3-dioxygenase (IDO) inhibitor for synergistic photoimmunotherapy through induction of immunogenic cell death and blockage of IDO pathway. Nano Lett. 19, 6964\u20136976 (2019).","journal-title":"Nano Lett."},{"key":"31579_CR53","doi-asserted-by":"publisher","first-page":"1700891","DOI":"10.1002\/advs.201700891","volume":"5","author":"J Peng","year":"2018","unstructured":"Peng, J. et al. Photosensitizer micelles together with IDO inhibitor enhance cancer photothermal therapy and immunotherapy. Adv. Sci. 5, 1700891 (2018).","journal-title":"Adv. Sci"},{"key":"31579_CR54","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.1039\/C9CS00773C","volume":"49","author":"C Zhang","year":"2020","unstructured":"Zhang, C. & Pu, K. Molecular and nanoengineering approaches towards activatable cancer immunotherapy. Chem. Soc. Rev. 49, 4234\u20134253 (2020).","journal-title":"Chem. Soc. Rev."},{"key":"31579_CR55","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/s41467-021-23194-w","volume":"12","author":"C Zhang","year":"2021","unstructured":"Zhang, C. et al. Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy. Nat. Commun. 12, 2934 (2021).","journal-title":"Nat. Commun."},{"key":"31579_CR56","doi-asserted-by":"publisher","first-page":"eabg8402","DOI":"10.1126\/scitranslmed.abg8402","volume":"14","author":"K Odunsi","year":"2022","unstructured":"Odunsi, K. et al. Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Sci. Transl. Med. 14, eabg8402 (2022).","journal-title":"Sci. Transl. Med"},{"key":"31579_CR57","doi-asserted-by":"publisher","unstructured":"Lee, R. et al. Synthetic essentiality of tryptophan 2,3-dioxygenase in APC-mutated 2 colorectal cancer. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0680 (2022).","DOI":"10.1158\/2159-8290.CD-21-0680"},{"key":"31579_CR58","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejso.2011.10.004","volume":"38","author":"ZM Rashaan","year":"2012","unstructured":"Rashaan, Z. M. et al. Surgery in metastatic breast cancer: Patients with a favorable profile seem to have the most benefit from surgery. Eur. J. Surg. Oncol. 38, 52\u201356 (2012).","journal-title":"Eur. J. Surg. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31579-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31579-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31579-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T12:53:26Z","timestamp":1669294406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31579-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["31579"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-31579-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,2]]},"assertion":[{"value":"25 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3821"}}